Online fireside chat: Creating a Powerful NAM respiratory Toxicology Strategy for Clinical Predictivity and IND success

Fireside chat with Dr Clive Roper and Dr Megan Webster

During this fireside chat session, you will hear our 2 guest speakers address standardisation, trends and innovations in respiratory in-vitro models to best devise a NAM (new approach methodologies) strategy to progress your respiratory compound through the pipeline

Speakers

Dr Clive Roper – Director  –  Roper Toxicology

Clive graduated with a PhD in in vitro dermal absorption followed by a post-doctoral position. In 1996, he joined CRL performing in vitro skin penetration studies, then promoted to Director, In Vitro Toxicology, leading the in vitro toxicology, genetox, safety pharmacology and advanced in vitro model’s teams. In 2021, Clive started a consulting business aiding clients in gaining adoption and regulatory acceptance of NAMs. Clive is the board chairperson for PeptiMatrix, board member of the 3Rs Collaborative and NC3Rs and Vice President of ESTIV. He is member of the Roundtable of Toxicology Consultants, American College of Toxicology and Society of Toxicology, a European Registered Toxicologist, and is a chartered biologist and chartered scientist and Fellow of Royal Society of Biology.

Dr Megan Webster – Principal Scientist/ Head of Lung platform – Newcells Biotech

Dr Megan Webster has been at Newcells since 2020 where she heads the Lung platform team. She has successfully led the development and launch of Newcells Fibroblast-to-Myofibroblast Transition (FMT) assay and Ciliary Beat Frequency Assay and continues to lead the development of a small airway model and an iPSC-derived model of the human pulmonary alveoli.

Following her PhD in collaboration with the DMPK department at AstraZeneca Megan completed her post-doctoral studies at the University of North Carolina, Chapel Hill where her research focused on the therapeutic modulation of ion transport in the upper airways, with a specific focus on Cystic Fibrosis disease modeling. Megan has worked as a Scientist within the Immunology & Respiratory department at Boehringer-Ingelheim where she designed and lead drug discovery programs ranging from PoC through to lead optimization and further developed her knowledge of lung disease, with a primary focus of IPF/ILD and application of in-vitro models for drug discovery.